{"id":"https://openalex.org/W1972591384","doi":"https://doi.org/10.1097/coh.0b013e32834b87f8","title":"Future of hepatitis C therapy","display_name":"Future of hepatitis C therapy","publication_year":2011,"publication_date":"2011-10-04","ids":{"openalex":"https://openalex.org/W1972591384","doi":"https://doi.org/10.1097/coh.0b013e32834b87f8","mag":"1972591384","pmid":"https://pubmed.ncbi.nlm.nih.gov/21897228"},"language":"en","primary_location":{"id":"doi:10.1097/coh.0b013e32834b87f8","doi":"https://doi.org/10.1097/coh.0b013e32834b87f8","is_oa":false,"landing_page_url":"https://doi.org/10.1097/coh.0b013e32834b87f8","pdf_url":null,"source":{"id":"https://openalex.org/S106953758","display_name":"Current Opinion in HIV and AIDS","issn_l":"1746-630X","issn":["1746-630X","1746-6318"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","medline","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in HIV and AIDS","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5052909853","display_name":"Gregory J. Dore","orcid":"https://orcid.org/0000-0002-4741-2622","observed_orcids":["https://orcid.org/0000-0002-4741-2622"]},"institutions":[{"id":"https://openalex.org/I31746571","display_name":"UNSW Sydney","ror":"https://ror.org/03r8z3t63","country_code":"AU","type":"education","lineage":["https://openalex.org/I31746571"]},{"id":"https://openalex.org/I4405258879","display_name":"Kirby Institute","ror":"https://ror.org/01bf9eh94","country_code":"AU","type":"facility","lineage":["https://openalex.org/I4405258879"]}],"countries":["AU"],"is_corresponding":true,"raw_author_name":"Gregory J. Dore","raw_affiliation_strings":["Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales, Australia. gdore@kirby.unsw.edu.au","e-mail: [email\u00a0protected]","fax: +61 2 9385 0920","to Professor Gregory J. Dore, The Kirby Institute, The University of New South Wales, CFI Building, Corner Boundary and West Streets, Darlinghurst, NSW 2010, Australia Tel: +61 2 9385 0900"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales, Australia. gdore@kirby.unsw.edu.au","institution_ids":["https://openalex.org/I31746571","https://openalex.org/I4405258879"]},{"raw_affiliation_string":"e-mail: [email\u00a0protected]","institution_ids":[]},{"raw_affiliation_string":"fax: +61 2 9385 0920","institution_ids":[]},{"raw_affiliation_string":"to Professor Gregory J. Dore, The Kirby Institute, The University of New South Wales, CFI Building, Corner Boundary and West Streets, Darlinghurst, NSW 2010, Australia Tel: +61 2 9385 0900","institution_ids":["https://openalex.org/I31746571","https://openalex.org/I4405258879"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054107081","display_name":"Gail V. Matthews","orcid":"https://orcid.org/0000-0002-1048-6396","observed_orcids":["https://orcid.org/0000-0002-1048-6396"]},"institutions":[{"id":"https://openalex.org/I31746571","display_name":"UNSW Sydney","ror":"https://ror.org/03r8z3t63","country_code":"AU","type":"education","lineage":["https://openalex.org/I31746571"]},{"id":"https://openalex.org/I4210087284","display_name":"St Vincent's Hospital Sydney","ror":"https://ror.org/000ed3w25","country_code":"AU","type":"healthcare","lineage":["https://openalex.org/I4210087284"]},{"id":"https://openalex.org/I4405258879","display_name":"Kirby Institute","ror":"https://ror.org/01bf9eh94","country_code":"AU","type":"facility","lineage":["https://openalex.org/I4405258879"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Gail V. Matthews","raw_affiliation_strings":["HIV, Immunology, Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, New South Wales, Australia","Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"HIV, Immunology, Infectious Diseases Clinical Services Unit, St Vincent's Hospital, Sydney, New South Wales, Australia","institution_ids":["https://openalex.org/I4210087284"]},{"raw_affiliation_string":"Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales","institution_ids":["https://openalex.org/I31746571","https://openalex.org/I4405258879"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054617732","display_name":"J\u00fcrgen Kurt Rockstroh","orcid":"https://orcid.org/0000-0003-2858-3888","observed_orcids":["https://orcid.org/0000-0003-2858-3888"]},"institutions":[{"id":"https://openalex.org/I135140700","display_name":"University of Bonn","ror":"https://ror.org/041nas322","country_code":"DE","type":"education","lineage":["https://openalex.org/I135140700"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"J\u00fcrgen Rockstroh","raw_affiliation_strings":["Department of Medicine I, University of Bonn, Bonn, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine I, University of Bonn, Bonn, Germany","institution_ids":["https://openalex.org/I135140700"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5052909853"],"corresponding_institution_ids":["https://openalex.org/I31746571","https://openalex.org/I4405258879"],"apc_list":null,"apc_paid":null,"fwci":4.6612,"has_fulltext":false,"cited_by_count":31,"citation_normalized_percentile":{"value":0.95092025,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"6","issue":"6","first_page":"508","last_page":"513"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10151","display_name":"Hepatitis C virus research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11495","display_name":"Animal Virus Infections Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1103","display_name":"Animal Science and Zoology"},"field":{"id":"https://openalex.org/fields/11","display_name":"Agricultural and Biological Sciences"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hepatitis-c-virus","display_name":"hepatitis C virus","score":0.8690000176429749},{"id":"https://openalex.org/keywords/direct-acting-antivirals","display_name":"direct-acting antivirals","score":0.9860000014305115},{"id":"https://openalex.org/keywords/telaprevir","display_name":"telaprevir","score":0.9750000238418579},{"id":"https://openalex.org/keywords/boceprevir","display_name":"boceprevir","score":1.0},{"id":"https://openalex.org/keywords/protease-inhibitors","display_name":"protease inhibitors","score":0.7639999985694885},{"id":"https://openalex.org/keywords/hiv-hcv-coinfection","display_name":"HIV/HCV coinfection","score":0.9589999914169312},{"id":"https://openalex.org/keywords/pegylated-interferon","display_name":"pegylated interferon","score":0.859000027179718},{"id":"https://openalex.org/keywords/ribavirin","display_name":"ribavirin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/sustained-virologic-response","display_name":"sustained virological response","score":0.9789999723434448},{"id":"https://openalex.org/keywords/interferon-free-therapy","display_name":"interferon-free therapy","score":0.7630000114440918},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.871999979019165},{"id":"https://openalex.org/keywords/hcv-genotype-1","display_name":"HCV genotype 1","score":0.7379999756813049}],"concepts":[{"id":"https://openalex.org/C2777159539","wikidata":"https://www.wikidata.org/wiki/Q410551","display_name":"Boceprevir","level":5,"score":0.9562488794326782},{"id":"https://openalex.org/C2778159067","wikidata":"https://www.wikidata.org/wiki/Q408557","display_name":"Telaprevir","level":5,"score":0.9511496424674988},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8432884216308594},{"id":"https://openalex.org/C2780040827","wikidata":"https://www.wikidata.org/wiki/Q421862","display_name":"Ribavirin","level":4,"score":0.6461621522903442},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6189088821411133},{"id":"https://openalex.org/C2776461080","wikidata":"https://www.wikidata.org/wiki/Q7160835","display_name":"Pegylated interferon","level":5,"score":0.6137208938598633},{"id":"https://openalex.org/C2777813720","wikidata":"https://www.wikidata.org/wiki/Q1243018","display_name":"Coinfection","level":3,"score":0.5015766620635986},{"id":"https://openalex.org/C2776455275","wikidata":"https://www.wikidata.org/wiki/Q154869","display_name":"Hepatitis C","level":2,"score":0.4974062740802765},{"id":"https://openalex.org/C2779343474","wikidata":"https://www.wikidata.org/wiki/Q3109175","display_name":"Context (archaeology)","level":2,"score":0.46982574462890625},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.46729424595832825},{"id":"https://openalex.org/C2776408679","wikidata":"https://www.wikidata.org/wiki/Q708693","display_name":"Hepatitis C virus","level":3,"score":0.4406784474849701},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.41965562105178833},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3995901346206665},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.3663247227668762},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3653109669685364},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3257490396499634},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.22810882329940796},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.1524372696876526},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.15076348185539246},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0593055784702301},{"id":"https://openalex.org/C151730666","wikidata":"https://www.wikidata.org/wiki/Q7205","display_name":"Paleontology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000998","descriptor_name":"Antiviral Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D009842","descriptor_name":"Oligopeptides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011392","descriptor_name":"Proline","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011392","descriptor_name":"Proline","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D011392","descriptor_name":"Proline","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011480","descriptor_name":"Protease Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D016174","descriptor_name":"Hepacivirus","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":false},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D019698","descriptor_name":"Hepatitis C, Chronic","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1097/coh.0b013e32834b87f8","doi":"https://doi.org/10.1097/coh.0b013e32834b87f8","is_oa":false,"landing_page_url":"https://doi.org/10.1097/coh.0b013e32834b87f8","pdf_url":null,"source":{"id":"https://openalex.org/S106953758","display_name":"Current Opinion in HIV and AIDS","issn_l":"1746-630X","issn":["1746-630X","1746-6318"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","doyens","medline","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Opinion in HIV and AIDS","raw_type":"journal-article"},{"id":"pmid:21897228","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21897228","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current opinion in HIV and AIDS","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":19,"referenced_works":["https://openalex.org/W1992668008","https://openalex.org/W1997514631","https://openalex.org/W2014495557","https://openalex.org/W2016010302","https://openalex.org/W2046658390","https://openalex.org/W2047556186","https://openalex.org/W2063285149","https://openalex.org/W2064546869","https://openalex.org/W2082828979","https://openalex.org/W2086414517","https://openalex.org/W2095563205","https://openalex.org/W2116848809","https://openalex.org/W2124541532","https://openalex.org/W2125963799","https://openalex.org/W2133104574","https://openalex.org/W2141214317","https://openalex.org/W2143559032","https://openalex.org/W2164211111","https://openalex.org/W2171945301"],"related_works":["https://openalex.org/W2153177038","https://openalex.org/W2119844106","https://openalex.org/W2043518660","https://openalex.org/W2014828596","https://openalex.org/W2008013516","https://openalex.org/W2142895379","https://openalex.org/W2045768063","https://openalex.org/W2162712320","https://openalex.org/W1965501706","https://openalex.org/W2052000792"],"abstract_inverted_index":{"PURPOSE":[0],"OF":[1],"REVIEW:":[2],"The":[3],"landscape":[4],"of":[5,22,63,74,179],"hepatitis":[6],"C":[7],"virus":[8],"(HCV)":[9],"therapy":[10,28,181],"will":[11,32,182],"change":[12],"considerably":[13],"over":[14],"the":[15,19,34,37,61,72,169,194],"next":[16],"decade":[17],"with":[18,91,104,147,193],"probable":[20],"licensure":[21],"many":[23,105],"HCV":[24,85,93,189],"direct-acting":[25],"antiviral":[26],"(DAA)":[27],"agents.":[29],"This":[30],"review":[31],"outline":[33],"data":[35],"on":[36],"initial":[38,120],"two":[39],"DAA":[40,157,180],"agents":[41,158],"licensed":[42],"(protease":[43],"inhibitors":[44],"telaprevir":[45,75,148],"and":[46,48,54,81,88,131,149,164,167],"boceprevir)":[47],"cover":[49],"potential":[50,132,195],"future":[51],"therapeutic":[52],"strategies":[53],"challenges":[55,136],"for":[56,137,171,196],"DAA-based":[57,121,174],"therapy,":[58],"including":[59],"in":[60,83,100,141,151,188],"context":[62],"HIV/HCV":[64,142,152],"coinfection.":[65,143],"RECENT":[66],"FINDINGS:":[67],"Phase":[68,144],"III":[69],"trials":[70,146],"evaluating":[71],"addition":[73],"or":[76],"boceprevir":[77,150],"to":[78,108,115,160,184],"pegylated":[79],"interferon":[80,172],"ribavirin":[82],"both":[84],"treatment":[86,111,122],"na\u00efve":[87],"experienced":[89],"populations":[90,153],"chronic":[92],"genotype":[94],"1":[95],"have":[96,161],"demonstrated":[97],"considerable":[98],"improvements":[99],"sustained":[101],"virological":[102],"response,":[103],"patients":[106],"able":[107],"shorten":[109],"total":[110],"duration":[112],"from":[113],"48":[114],"24-36":[116],"weeks.":[117],"Although":[118],"these":[119],"results":[123],"are":[124,154],"encouraging,":[125],"additional":[126],"toxicity,":[127],"problematic":[128],"dosing":[129,165],"schedules,":[130],"drug-drug":[133],"interactions":[134],"pose":[135],"clinical":[138,190],"management,":[139,191],"particularly":[140,192],"II":[145],"underway.":[155],"Subsequent":[156],"appear":[159],"improved":[162],"tolerability":[163],"schedules":[166],"open":[168],"door":[170],"(IFN)-free":[173],"combination":[175,198],"therapy.":[176,199],"SUMMARY:":[177],"Development":[178],"lead":[183],"a":[185],"major":[186],"shift":[187],"IFN-free":[197]},"counts_by_year":[{"year":2024,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":7}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}